CN105749159A - Application of traditional Chinese medicine for treating psoriasis in preparation of medicine for treating multiple sclerosis - Google Patents
Application of traditional Chinese medicine for treating psoriasis in preparation of medicine for treating multiple sclerosis Download PDFInfo
- Publication number
- CN105749159A CN105749159A CN201610188338.3A CN201610188338A CN105749159A CN 105749159 A CN105749159 A CN 105749159A CN 201610188338 A CN201610188338 A CN 201610188338A CN 105749159 A CN105749159 A CN 105749159A
- Authority
- CN
- China
- Prior art keywords
- multiple sclerosis
- treating
- weight portion
- medicine
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of a traditional Chinese medicine for treating psoriasis in preparation of a medicine for treating multiple sclerosis.The medicine for treating the multiple sclerosis is prepared from, by weight, 15 parts of glabrous sarcandra herb, 9 parts of rhizoma curcumae, 60 parts of rhizoma smilacis glabrae, 9 parts of radix paeoniae rubra, 15 parts of dark plum fruit, 15 parts of sinkiang arnebia roots and 6 parts of licorice roots.The medicine for treating the multiple sclerosis can improve the neurological function, reduce pathologic changes such as inflammatory cell infiltration of the cerebral white matter area and spinal cord and reduce formation of vascular cuffing, myelinoclasis and neuronal cell vacuole necrosis, and therefore the purpose of treating the multiple sclerosis is achieved.
Description
Technical field
The present invention relates to medical preparation, be specifically related to containing the pharmaceutical preparation not determining structure carrying out plant.
Background technology
Multiple sclerosis (MultipleSclerosis, it is called for short MS) it is that a kind of chronic progressive external is with central nervous system (CentralNervousSystem, CNS) white matter demyelinating disease becomes feature, sickness rate in American-European countries is 177-350/100000, Asia sickness rate is on the rise, because it has higher relapse rate, society is brought heavy medical treatment and financial burden by the chronic course of disease, especially person between twenty and fifty are susceptible to suffer from (being apt to occur in 20-40 year, women is common, the ill ratio of men and women is about 1:2), the commonly encountered diseases that disables of its atraumatic because of, have a strong impact on quality of life, so extremely pay attention to always.The principal pathogenetic pattern of MS has four kinds: relapsing-remitting type (Relapsing-Remitting, RR), former-Advancement Type (Primary-Progressive, PP), secondary progressive (Secondary-Progressive, and progress-relapsing (Primary-Relapsing, PR) SP).The course of disease is often with acute or subacute onset, and after last from days, symptom has alleviation in various degree, after alleviating several weeks or several months, and symptom recurrent exerbation.Clinical characters all shows as focus and sends out extensively, can simultaneously or sequentially involve brain, cerebellum, brain stem and spinal cord, often has the brain of intermittent attack, spinal cord and optic nerve nervous lesion in the course of disease, including visual disorder, ataxia, motion and anesthesia, intestinal and bladder incontinence etc..These inflammation are recurrent exerbation in alba and spinal cord, cause that a large amount of inflammatory cell cumulative distribution is around alba and spinal cord blood vessel, oligodendrocyte, neuron and axon are destroyed, form the performance of alba demyelination, make function of nervous system's transient state damage or permanent loss, may finally disable time serious.
The cause of disease of MS is still not clear, but big quantity research shows that MS is probably on the basis of tumor susceptibility gene, impact and viral infection by some environmental factors trigger and cause that self immune system suffers harmful effect, thus causing the impaired a kind of pathological changes of nerve sheath inflammation, it have been recognized that MS pathology are to be infiltrated central nervous system by autoreactive T cell, subsequently the myelin of CNS is produced immune attack, therefore MS is considered as a kind of autoimmune disease.
There is no treatment multiple sclerosis (MS) specific medicament at present to come out, therapeutic goal simply " reduces recurrence frequency, delays PD ", main purpose is the progress suppressing Demyelmating disease to become, prevent acute stage pathological changes from worsening and catabasis recurrence, glucocorticoid (the Glucocorticoid that doctor trained in Western medicine is conventional, GC) and immunosuppressant treatment, also rise in the treatment of MS gradually neutralizing the biological preparation (such as natalizumab) that inflammatory factor is target in addition.Though these medicines can make acute stage shorten, but still its recurrent exerbation can not be changed and cause the course of disease that sb.'s illness took a turn for the worse, and said medicine uses for a long time in a large number, obvious side effect can be caused.
Relevant from theory of Chinese medical science analysis, the MS cause of disease and being invaded by exogenous pathogen, feelings will not easypro, excessive, the congenital deficiency of kidney-essence of eating and drinking without temperance, impairment caused by overstrain etc..Its pathogenesis mainly includes several aspects such as positive exogenous pathogen visitor, kidney yang virtual loss, the hepatic and renal YIN deficiency, taste deficient qi and blood, stagnation of phlegm-damp in middle-JIAO, blood stasis due to qi deficiency.Reporting analysis and summary from clinical experience and clinical literature, suffer from a deficiency of the kidney and blood stasis is the main pathogenesis of primary disease, sick position is at brains, relevant with kidney,liver,spleen etc., especially in close relations with kidney, and blood stasis is also the pathological factor that primary disease is important.All doctor's differentiation of symptoms and signs for classification of syndrome acute stage many genus rheumatism, damp and hot, phlegm stagnation in collateral etc., the catabasis is many suffers from a deficiency of the kidney based on liver spleen, the card of phlegm stagnation in collateral.Expectorant stasis blocking is stagnant runs through disease all the time, treatment on should with eliminating phlegm and clearing away heat, disperse blood stasis and dredge collateral for method, modern pharmacological research proves, Chinese medicine particularly the kidney invigorating, blood circulation promoting and blood stasis dispelling product, scalable body's immunity, there is antiinflammatory, anti-allergic effects, the resistance of body can be improved.Prompting theory of Chinese medical science in have blood circulation promoting and blood stasis dispelling hold concurrently regulate autoimmune function Chinese medicine, it is understood that there may be improve the effective ingredient of MS symptom, MS be likely to be of potential therapeutical effect.
Autoreactive T cell is at central nervous system (Centralnervoussystem, CNS) it is reactivated around blood vessel, specific T-cells, monocyte infiltration around cerebral tissue and spinal cord blood vessel, form the important pathological characteristics that axon demyelination is MS.Thl/Th17 dysequilibrium in helper T lymphocyte (helperTcell, Th) is the key factor of MS formation and development.In addition, under the adjustment of cytokine, it may happen that mutually convert between Th cell subsets, and produce corresponding immune response, interaction between immunity regulatory cell and relevant cytokine just forms an indivisible network, and the combined effect between them has promoted the formation and development of MS.We may safely draw the conclusion, reduces inflammatory reaction, and the balance regulating Th cell subsets becomes the key for the treatment of MS.
With myelin oligodendrocyte glycoprotein (MyelinOligodendrocyteGlycoprotein, MOG) polypeptide fragment immune induction experimental autoimmune encephalomyelitis model (ExperimentalAutoimmuneEncephalomyelitis, EAE) it is a kind of cell-mediated based on specificity sensitization CD4+T, the autoimmune disease that mononuclear cells infiltration is feature occurs around thin vessels in central nervous system, MS can be simulated pathogenesis, and reproduced the clinical disease course of various MS type；Its pathological change also has the typical feature such as inflammatory cell infiltration, myelinoclasis, axonal degeneration.Current EAE has become one of MS preclinical study and basic T cell the most successful immunologic animal model, organ specific autoimmune's property disease that it not only summarises is prototype with MS pathological characteristic, may also be used for as studying the internal T cell immunoreactive appropriate model of growth simultaneously.
At present, domestic and international multinomial research finds, Chinese medicine passes through the expression of the unbalance state of regulatory T-cell subgroup and the related inflammatory factor, to autoimmune disease, as EAE serves certain therapeutic effect.The Radix Tripterygii Wilfordii therapeutic intervention 42 example MS clinical patients such as Liu Ruihua, before and after the treatment of Tripterygium Wilfordii Hook group, in peripheral blood, CD4+T cell substantially reduces before relatively treating, CD8+T cell substantially increases, CD4+/CD8+ ratio then significantly reduces, and illustrates that the immunosuppression mechanism of Tripterygium Wilfordii Hook multiple sclerosis may be by regulating t lymphocyte subset group distribution and playing a role.Research is confined to Chinese medicine monomer or active component more, and the research of traditional Chinese medicine composition for treating multiple sclerosis is little.Clinical studies show, Chinese medicine MS is many to be cut out with Tonifying Kidney Recipeization.Such as benefit curing capsule (Radix Ginseng, Cornu Cervi Pantotrichum, Semen Cuscutae, Radix Polygoni Multiflori, Fructus Lycii etc.), two yellow stuff (Radix Rehmanniae, Radix Rehmanniae Preparata, Radix Polygoni Multiflori Preparata etc.), Bushen Gusui tablet (Herba Epimedii, Herba Cistanches, Rhizoma Curculiginis, Radix Rehmanniae, Radix Polygoni Multiflori Preparata etc.), Glutinous Rehmannia Mixture (Radix Rehmanniae Preparata, Fructus Corni etc.), Testudinis deer Bone marrow benefiting capsule for treating anemia (Radix Ginseng, Cornu Cervi Pantotrichum, Carapax et Plastrum Testudinis, Semen Cuscutae, Radix Polygoni Multiflori, Fructus Lycii etc.), Yishendaluoyin (Radix Rehmanniae Preparata, Colla cornus cervi etc.), Bolus as a Kidney-Yin-Tonic, Yougui Wan, the kidney-Yang-Reinforcing Bolus (Radix Rehmanniae Preparata, Semen Cuscutae, Radix Achyranthis Bidentatae, Colla Plastri Testudinis, Colla cornus cervi, Fructus Lycii etc.) Coryza Treated by Syndrome Differentiation MS patient.Experimentation shows that Bolus as a Kidney-Yin-Tonic can lower Thl/Th2 level in EAE acute stage plasma, Bolus as a Kidney-Yin-Tonic and Yougui Wan, the kidney-Yang-Reinforcing Bolus all can raise EAE catabasis blood plasma Thl/Th2 level, improve the EAE symptom of Lewis rat, it is believed that the two Partial Mechanism place being probably Chinese herb decoction opinion treatment acute stage MS by lowering TNF-α, MMP-9 expression, rise IL-12p40 and TGF-β to express.The mechanism of action that king's equality treats MS by two yellow party (Radix Rehmanniae, Radix Rehmanniae Preparata, Radix Polygoni Multiflori Preparata etc.) may be by the MCP-1 in downward Cerebrospinal Fluid in Patients and raises TGF-β, thus playing the effect reducing recurrence.
Publication number is that the patent application of CN101632827A discloses one and treats psoriatic Chinese medicine composition, said composition is the preparation made containing, for example lower raw material: Herba Sarcandrae 3～30 parts, Rhizoma Curcumae 3～30 parts, Rhizoma Smilacis Glabrae 2～60 parts, Radix Paeoniae Rubra 5～30 parts, Fructus Mume 2～30 parts, Radix Arnebiae (Radix Lithospermi) 2～50 parts, 1～10 part of Radix Glycyrrhizae.The prescription of this patent application has effect of blood enriching and dryness moistening, removing pathogenic heat from blood and toxic substance from the body, disperse blood stasis and dredge collateral, is clinically used for the psoriasis determined curative effect for the treatment of blood-deficiency and wind-dry type.
Modern pharmacological research shows, Etretinate Chinese medicinal components has multiple pharmacologically active, all body's immunity and inflammatory reaction is produced impact, and overview gets up to say, the pharmacological action of current published bibliographical information is as follows:
(1) in side in the index components such as the Herba Sarcandrae that contains containing the compound such as chlorogenic acid, rosmarinic acid, there is the effect (Feng Limin such as antiinflammatory, immunosuppressant, Zhao Ruizhi, Wang Yinjie, Han Ling, Lu Chuanjian. the extraction process [J] of Herba Sarcandrae effective ingredient in the preferred Etretinate sheet of orthogonal design. time treasure's traditional Chinese medical science traditional Chinese medicines, 2011,08:1860-1861.).
(2) shikonin in red bar Radix Arnebiae (Radix Lithospermi) can reduce Th1 cytokines expression, make Th2 cytokines express and increase (Dai Qiaomei, Wang Jinfeng, Zhang Fengshan. shikonin is to the arthritic Effect study of late collagen [J]. Harbin Medical University's journal, 2009,43 (1): 48-51.).
(3) Rhizoma Curcumae can significantly improve mice immunologic function (Li Faqing, Di great Lin, Chen Lei. the research [J] that immune function of mice is affected by Rhizoma Curcumae. time treasure's traditional Chinese medical science traditional Chinese medicines, 2006,17 (8): 1482-1483.).
(4) Rhizoma Smilacis Glabrae and effective ingredient astilbin thereof can suppress the migration of activating T cell and the expression of CD4+, immunoreation is made to have Th1 type to offset to Th2 type, immunne response is produced inhibitory action (FeiM, WuX, XuQ.Astilbininhibitscontacthypersensitivitythroughnegati vecytokineregulationdistinctfromcyclosporinA [J] .JAllergyClinImmunol.2005,116 (6): 1350-1356；Chen Tao, Pan Tiecheng, Gao Sihai etc. the astilbin inhibitory action [J] to mouse heart grafts rejection. Shandong medicine, 2006,46 (33): 7-8.).
(5) ulcerative colitis is had therapeutical effect by Fructus Mume, anti-inflammatory cytokines can be raised, lower the effect of proinflammatory cytokine, immunologic function is made to recover normal (model perseverance, Qiu Mingyi, Mei Jiajun etc. the wumei pills intervention effect [J] to ulcerative colitis in rats histiocytokine. Chinese Clinical rehabilitation, 2006,10 (7): 87-89.).
(6) Radix Glycyrrhizae acids has Immunestimulatory effect, can strengthen multiplication capacity and the activity of helper T cell.Angelica Polysaccharide " coumarin " also has the effects such as antiinflammatory spasmolytic.Radix Glycyrrhizae extract body specific immunity is had certain facilitation (Gao Zhangtu, Zhang Jianxin, Xu Duo. glycyrrhizic acid antiinflammatory antiviral and Study immune regulation progress [J]. PLA's Acta Pharmaceutica Sinica, 1999,15 (5): 27；Liu Liping, Ren Cuiai, Zhao Hongyan. Study immune regulation progress [J] of glycyrrhizic acid. Chinese experimental pharmacology of Chinese medical formulae magazine, 2010,16 (6): 272-276；Zhu Xuefeng, thanks to roc etc. the bacteriostasis of Radix Glycyrrhizae extract and the impact [J] on immune function of mice thereof. and China's microecology magazine, 2013,25 (3): 254-257.).
(7) Chinese medicine extraction liquid stimulates the inhibited (Lu Chuanjian of the IL-8 produced for TNF-α, Liu Fengnian. tumor necrosis factor-alpha is stimulated the impact [J] of relief angle protein cell secretion of cytokines IL-8 by " Etretinate sheet " Chinese medicine extraction liquid. Liaoning Journal of Traditional Chinese Medicine, 2009,11:1862-1863.).
(8) full side is by improving pathological changes microcirculation, inflammatory reaction is suppressed to have therapeutical effect (Liao Liehui for psoriasis vulgaris (the stagnant skin type of the stasis of blood), Huang Yongjing, Fan Ruiqiang, state ties up. Huoxue Therapeutic Method psoriasis vulgaris (the stagnant skin type of the stasis of blood) 47 example observation of curative effect [J]. and the new traditional Chinese medical science, 2005,37 (12): 40-41.).
More than study prompting, Etretinate sheet has the effect such as antiinflammatory, immunosuppressant, Human Keratinocytes strain propagation has the effect of suppression and apoptosis, and epithelial cell mitosis can be suppressed to play the effect that suppression epidermal hyperplasia is too fast, at present, Etretinate sheet is applied clinically as treating psoriatic medicine, there is not yet the research report being applied to preventing and treating MS.
Summary of the invention
The technical problem to be solved in the present invention is to provide treatment psoriasis Chinese medicine new application in pharmacy.
Described treatment psoriasis Chinese medicine new application in pharmacy is specifically:
The application in preparation treatment multiple sclerosis agent of the treatment psoriasis Chinese medicine, wherein, the effective ingredient of described treatment multiple sclerosis agent to prepare raw material identical with the crude drug treating psoriasis Chinese medicine composition that publication number is CN101632827A patent application publication, be namely made up of following crude drug:
Herba Sarcandrae 15 weight portion, Rhizoma Curcumae 9 weight portion, Rhizoma Smilacis Glabrae 60 weight portion, Radix Paeoniae Rubra 9 weight portion, Fructus Mume 15 weight portion, Radix Arnebiae (Radix Lithospermi) 15 weight portion and Radix Glycyrrhizae 6 weight portion.
Described effective ingredient in above-mentioned application is made up of following methods:
(1) by described crude drug, directly smash into coarse powder to pieces, add the ethanol extraction twice that 8-10 times amount volumetric concentration is 70%, each 2 hours, united extraction liquid；
(2) concentrating under reduced pressure, reclaims ethanol, prepares extractum.
Treatment multiple sclerosis agent of the present invention can be added medically acceptable adjuvant by above-mentioned effective ingredient and make the oral formulations of routine, and every consumption per day of being grown up is equivalent to above-mentioned effective ingredient 2.15g crude drug/kg body weight, 21 days courses for the treatment of.
Treatment multiple sclerosis agent of the present invention can improve function of nervous system, reducing the pathological change in alba district and spinal cord, such as inflammatory cell infiltration, minimizing " vascular cuffing " is formed, myelinoclasis and neuronal cell cavity sample are downright bad, thus reaching the purpose for the treatment of multiple sclerosis.
In order to be more fully understood that the present invention, it is further elucidated with described treatment psoriasis Chinese medicine effect in preventing and treating multiple sclerosis following by embodiment and zoopery.
Accompanying drawing illustrates:
Fig. 1 is the curve chart compared with the C57BL/6 female mice inducing experimental autoimmunity cerebrospinal meningitis animal model sickness rate of MOG35-55 immunity, body weight mean and Neuroscore.
Fig. 2 is brain and the myeloid tissue HE dyeing picture of mice after modeling.
Fig. 3 is the result block diagram of the Q-PCR of inflammatory factor in Mice brain tissues.
Fig. 4 is the result block diagram of the Q-PCR of inflammatory factor in mouse spinal cord tissue.
Detailed description of the invention
Medicine used by following effect experiment is all the tablet (namely following Etretinate sheet) that prescription and preparation method described in CN101632827A patent application embodiment 1 are made by publication number.
One, Etretinate is to MOG(35-55)The adjustment effect experiment of Th cell subsets in the EAE central nervous system of mice of induction
Materials and methods:
1, animal origin
Obtaining from Guangzhou province Experimental Animal Center (GuangZhou, China), 30 18～22 grams of female C57BL/6 mices, adaptability is fed 1 week.Raising under mice specific pathogen free concrete conditions in the establishment of a specific crime, temperature is 24 ± 1 DEG C, and humidity is h light/12,40-80% and 12 h dark cycle.
2, instrument and material
Myelin oligodendrocyte glycoprotein (MOG (35-55): MEVGWYRSPFSRVVHLYNGK) (BioGenscript company, purity is more than 95%), complete good fortune formula adjuvant (CFA) (Sigma company), tuberculin (MT) (Difco company), pertussis toxin, PT (PTX), ListBiologic company).nullCD3 antibody (Abcom company)，Lowlenthal serum、Rabbit two resists、DAB nitrite ion (Maxim company)，RNA Reverse Transcriptase kit (Promega company)，Primer synthesis (LiuheGenomics company)，SYBRGreensupermix (Bio-rad company)，Cryogenic refrigerator (Sanyo，Japan)，Ultra cold storage freezer (U.S. Pedicellus et Pericarpium Trapae，China)，Homogenizer (BD，The U.S.)，Table-type high-speed refrigerated centrifuge (Eppendorf company，Germany)，RT-PCR instrument、Electrophoretic apparatus (Bio-Rad company，The U.S.)，7500 sequence quantitative real time PCR Instruments (application Blosystems，The U.S.) and PM-30 inverted microscope-Computer digital image analysis (Olympus，Japan).
3, drug solution preparing
Specify according to " herbal pharmacology experimental methodology ", the selection of mice dosage calculates according to the direct convert formula of dose,equivalent between different genera animal, it is grown up daily 129g crude drug, the dosage of mice is 12 times of adult, taking the described Etretinate extractum addition abundant suspendible of distilled water and be configured to every milliliter of suspension containing crude drug amount 2.58 grams, 4 DEG C save backup.
4, immunity modeling
By MOG35-55 (10mg/mL, it is configured to respective concentration with PBS after sterilizing) (mycobacterium tuberculosis (MT) containing 500 μ g inactivations is fully emulsified with sterilized glass syringe in the sixth of the twelve Earthly Branches with isopyknic CFA, along its back part median line both sides, divide at 2 to mouse back subcutaneous injection (l00 μ L/ is only) emulsion, the each 50 μ L in each position, finally MOG35-55 and the MT dosage of every mouse subcutaneous injection is 200 μ g.Every mouse peritoneal injection 300ng pertussis toxin, PT (PTX) was given after the immune same day and 72 hours.
5, packet and administration:
Mice is randomly divided into EAE model group (10), Etretinate sheet treatment group (10), Normal group (10), totally 3 groups.Starting preventive administration the previous day in modeling, once a day, Etretinate treatment group gives Etretinate suspension (25.8g crude drug/kg) gavage, and EAE model group and Normal group such as give at dosage distilled water gavage, the continuous gastric infusion 21 days.Dosage used obtains all in accordance with the conversion of human body consumption.
6, Monitoring Indexes:
(1) Avoirdupois monitoring: adopt double-blind method, once a day mice weighed, assess.
(2) mouse Nerve function monitoring: every day 2, people pressed Benson standards of grading in the same time at least 1 time, and EAE seriousness is carried out clinical assessment.
Benson standards of grading
0 point: without any clinical symptoms；
1 point: afterbody tension force disappears, it is seen that minor gait is clumsy；
2 points: double; two hind limb weakness, can recover after passively standing up；
3 points: double; two hind limb paralysis, can not recover after passively standing up, but can move after giving stimulation；
4 points: double; two hind limb paralysis, fore-limb paralysis or muscular strength weaken companion's urinary incontinence；
5 points: moribund condition or death.
Note: symptom between both standards person in soil 0.5." integral mean value every day " by all animal score value summations in same day group divided by this treated animal quantity gained.
(3) sickness rate monitoring: by Benson standards of grading, EAE clinic Neuroscore >=1 point person is decided to be morbidity, carries out the calculating of sickness rate.
7, tissue sampling:
Often group experiment mice is drawn materials for the 21st day after modeling immunity: cervical dislocation is put to death, take brain and spinal cord lumbar vertebra bulb tissue, tissue is cleaned with PBS, filter paper substantially blots brain and myeloid tissue's surface moisture, tissue is equally divided into 3 parts, and it is to be measured that a part processes sample according to real time fluorescence quantifying PCR method requirement；When observing for Hematoxylin-eosin (H&E) dyeing, after the portion of tissue required for taking out fixes 24 hours in 10% neutral formalin solution, dehydration, paraffin embedding, 3.5 μm of serial section row H&E dyeing.Another part takes flesh tissue and is covered in frost embedding liquid (OCT) and is put in rapidly in liquid nitrogen and cools down, and-80 DEG C save backup, and 5 μm of frozen sections are for SABC.
8, histopathology and evaluation index:
null(1) Hematoxylin-eosin (Hematoxylin-eosin，HE) dyeing: carry out the section of paraffin sample with paraffin slicing machine，Thickness 3.5 μm，Serial section，Dyeing procedure dries 20 minutes for roasting sheet，Dimethylbenzene 2 times × 10 minutes，Dehydrated alcohol 2 times × 2 minutes，95% ethanol 1 minute，80% ethanol 1 minute，70% ethanol 1 minute，Wash 1 minute，Haematoxylin 8 minutes，Haematoxylin 10 minutes，Wash 2 times × 1 minute，0.5% hydrochloride alcohol 10 seconds，Wash 10 minutes，2 minutes, Yihong，Wash 1 minute，80% ethanol 5 seconds，85% ethanol 5 seconds，90% ethanol 5 seconds，95% ethanol 1 minute，Dehydrated alcohol 2 times × 2 minutes，Dehydrated alcohol 3 minutes，Dimethylbenzene 2 times × 2 minutes，Direct neutral gum mounting after terminating dyeing.
(2) according to Okuda pathological score standard, picture that HE is dyeed is analyzed.Each sample slice takes 5 high power field (× 400) pictures, and each section is from alba, hippocampus and what substantia alba medullae spinalis district randomly choosed.Standards of grading are as follows:
(3) SABC (CD3) colouring method: 1. cut into slices, fix :-80 DEG C are taken out section, put in acetone, fix 20 minutes for 4 DEG C.2. PBS 3 times, each 3 minutes.2. disappear enzyme: eliminates endogenous peroxydase, incubated at room 10 minutes with 3% hydrogen peroxide/methanol.3. PBS 3 times, each 3 minutes.4. close with two anti-same derived sera (animal non-immune sheep serum), incubated at room 30 minutes.5. incubating primary antibodie: dilute with antibody diluent, put into 4 DEG C of overnight incubation in moisture preservation box, 16 hours, need to set PBS negative control, Sample Positive comparison and Sample Negative compare, and batch does and needs to do antibody concentration gradient before, find optimum condition.6. rewarming: next day, takes out section, room temperature rewarming 30 minutes.7. PBS 3 times, each 5 minutes.8. incubate two to resist: because primary antibodie is rabbit source anti-mouse antibody, so two anti-selection goat-anti rabbits two resist, instant, incubated at room 15 minutes.9. PBS 3 times, each 5 minutes.10. diaminobenzidine (DAB) colour developing: develop the color 3 minutes under light-avoiding spectacles.Tap water, haematoxylin is redyed 30 seconds, tap water, and 0.5% hydrochloride alcohol breaks up 10 seconds, and PBS returns indigo plant.Dehydration: 70% ethanol 1 time × 3 minutes, 95% ethanol 1 time × 3 minutes, dehydrated alcohol 1 time × 3 minutes, transparent 1 time × 3 minutes of dimethylbenzene.Neutral gum mounting.
(4) about the quantitative analysis of immunity image, undertaken by Image-ProPlus6.0 system.Often group takes 5 samples, and each sample takes 5 high power field (× 400) pictures, and each section is from alba, hippocampus and what substantia alba medullae spinalis district randomly choosed.Positive findings average optical represents.(average optical (meandensity)=integral optical density (IODSUM)/Area)
9, total tissue RNA is extracted and is separated:
100g tissue is moved to and toasts in the mortar of 8 hours with pre-cooling through 180 DEG C, grind specimen to powdered, process of lapping is continuously added liquid nitrogen；Add appropriate trizol cracking tissue and grind；Ambient temperatare is put 3-5 minute, is moved in clean microcentrifugal tube without enzyme by lysate after to be liquefied.Add the chloroform 0.2mL of pre-cooling, mixing of firmly turning upside down rapidly, stand 5 minutes on ice, make protein complexes all crack, centrifugal (4 DEG C, 13000g, 15 minutes).Drawing upper strata aqueous phase, transfer to another without, in enzyme centrifuge tube, adding 400 μ L isopropanols, mixing of firmly turning upside down rapidly ,-20 DEG C stand 30 minutes, precipitate RNA.Centrifugal (4 DEG C, 13000g, 10 minutes), a little white precipitate as seen at the bottom of pipe, removes supernatant, adds 70% ethanol (now joining with without enzyme water) of 1mL, wash roguing, on ice placement 5 minutes after mixing of turning upside down.Centrifugal (4 DEG C, 7600g, 5 minutes), blot ethanol as far as possible, dry 5 minutes under room temperature, treat that the ethanol volatilization of remnants is completely transparent to RNA precipitate, be eventually adding 30 μ L nuclease free water, dissolve RNA.
10, reverse transcription cDNA:
The synthesis of cDNA is carried out according to the program (table 1) in test kit description.Example reaction system 4 μ L contains 2.5 μ gRNA and random primer 1 μ L, adds nuclease free water to 5 μ L, and 70 DEG C are heated 5 minutes.In freezing at least 5 minutes immediately on ice, add Reverse transcription mix 15 μ L, brief centrifugation 10 seconds.Mixing after annealing heating hatches 5 minutes, extension heating 1 hour to 42 DEG C to 25 DEG C, takes out ,-20 DEG C of preservations after being cooled to 4 DEG C.
Reverse transcription mix is as follows:
11, RealTime-PCR analyzes:
The real time reaction system of 10 μ L contains: the universalSYBRGreensupermix (2x) of 5 μ L, the 0.5 μ L (10 μm of ol/L) of forward primer, 0.5 μ L (10 μm of ol/L), the cDNA4 μ L of dilution of downstream primer.
Covering 96 hole PCR plate with fluorescent quantitation special-purpose sealing film, put into quantitative real time PCR Instrument after brief centrifugation, expand 40 circulations, degeneration, annealing, extension are temperature required, time respectively 95 DEG C of 30s, 60 DEG C of 30s, 72 DEG C of 90s.
CD3 ε as reference gene, each sample replication 3 times.The relative quantity Ct value of mRNA represents, average relative expression passes through 2-△ △ CtANALYSIS OF CALCULATING.
The primer sequence is as follows:
12, statistical procedures:
Experimental data adopts SPSS17.0 software to carry out statistical analysis, and measurement data all represents with mean ± standard deviationComparing application ANOVA variance analysis between the group of measurement data mean, P < 0.05 has statistical significance；Enumeration data adopts X 2 test, and P < 0.05 has statistical significance；Ranked data adopt Kruskal-Wallis method in rank test to test, and P < 0.05 has statistical significance.
Two, interpretation of result
1. Etretinate is to MOG(35-55)EAE mouse invasion rate, the impact of body weight and the protective effect to nervous function induced
In whole experimentation, normal group mice is without morbidity, and reaction, activity, appetite are all normal, and body weight is gradually increased.After antigen immune is induced 7 days, model mice starts morbidity gradually, clinical manifestation is bradykinesia, movable minimizing, loses weight, and obvious nervous system signs occurs: hind limb paralysis unable with tail drop, double; two are common, part severe patient extremity are all paralysed, are even moribund condition, symptom all meets the performance of EAE mouse model, and prolongation in time increases the weight of gradually.Within 14th day, reach onset peak, then begin to neurological functional recovery.Two groups of mices are after MOG antigen immune, and sickness rate all can reach 100% (p<0.0001), and Etretinate group and model group are without significant difference (p>0.05), and modeling success (see table 1, Figure 1A) is described；After modeling before the 14th day peak period, EAE model group Mouse Weight has no and substantially alleviates, normal group, model group and Etretinate administration group three groups compare, p=0.00528>0.05, no difference of science of statistics, but the 14th day onset peak period, all there is progression of disease to some extent in mice, the model group body weight of MOG induction reduces substantially, and after Etretinate therapeutic intervention, Mouse Weight not only has no and substantially alleviates, compared with normal group increases to some extent on the contrary, p=0.0025<0.01, there is significant difference in statistical analysis, illustrate that Etretinate can make EAE mice increase (see table 2 in acute onset middle and advanced stage body weight, Figure 1B)；And after using the treatment of Etretinate extractum aqueous solution gavage, the occurring degree of mice relatively model group is light, Neuroscore is remarkably decreased (p=0.0244 < 0.05) (see table 3, Fig. 1 C), statistically significant, illustrates that Etretinate can improve EAE mouse Nerve function.
Table 1: each group mouse invasion rate compares (percentage ratio)
Note: compared with Normal group, P < 0.0001, there is significant difference, modeling immune success rate is described.
Table 2: (gram) is compared in each group Mouse Weight change
Note: acute onset early stage, three groups of body weight means compare, p=0.00528 > 0.05, no difference of science of statistics；Acute onset middle and advanced stage, YXL group compared with Normal group, model group, p=0.0025 < 0.01, have significant difference.
Table 3: each group mouse Nerve function score compares
Note: Etretinate treatment group compared with EAE model group, p=0.0244 < 0.05, have significant difference.
2. Etretinate is to MOG(35-55)The EAE central nervous system of mice pathological lesion of induction has improvement result
The brain of Etretinate liquid medicine applying EAE mouse model and myeloid tissue find through HE dyeing and Immunohistochemical Method (CD3 ε) dyeing, Normal group mouse tissue shows no obvious abnormalities change, there are multiple position in the visible brain of immune model group mice and myeloid tissue, massive inflammatory cells infiltrated around blood vessel, thin vessels is substantially expanded, around part blood capillary by inflammatory cell around, form typical " blood vessel oversleeve sample " to change, the pathological characteristics such as glial cell demyelination and the necrosis of neuronal cell cavity sample change, above-mentioned change is with cerebral white matter district, tricorn hippocampus and substantia alba medullae spinalis district are the most notable, part skin medullary junction place also may occur in which；And the more high person of Neuroscore, the degree of inflammatory lesions scope and cellular infiltration also increases accordingly；To HE dye picture through row Okuda histological scores find, model group major part be in-severe inflammatory infiltration, inflammatory cell infiltration quantity is more, and scope is wider；And in Etretinate treatment group mouse brain and myeloid tissue, also show inflammatory cell infiltration, downright bad with a small amount of neuronal cell cavity sample, but extent of disease, quantity relatively model group significantly reduces, only a few visible " blood vessel oversleeve sample " changes (see table 4,5 and Fig. 2).
Each group brain and myeloid tissue's frozen section SABC, the Infiltrating of total T lymphocyte (CD3 ε) in acute phase of disease mouse tissue after observing immune 21 days, picture amplification is 400 times；Normal group, has no obvious T lymphocytic infiltration；EAE model group, it is seen that inflammatory cell infiltrates in a large number, is gathered in around part thin vessels；In Etretinate treatment group, inflammatory lesions scope and quantity relatively model group reduce, often group takes 5 samples, each sample takes 5 visual field pictures and is averaged optical density IOD value quantitative analysis and statistics, the average optical density value that model group CD3 ε expresses is higher than YXL group (P < 0.05), statistically significant (see table 6).
Table 4: each group mice treatment tissues following MCAO in rats pathology score distribution and encephalitis light and heavy degree distribution percentage rate (percentage ratio=each score distribution number of cases/respectively organize total number of samples × 100%)
Note: Etretinate treatment group compares with model group, p=0.0088 < 0.01 has significant difference.
Table 5: myeloid tissue's pathology score distribution and myelitis light and heavy degree distribution percentage rate (percentage ratio=each score distribution number of cases/respectively organize total number of samples × 100%) after each group mice treatment
Note: Etretinate treatment group compares with model group, p=0.0036 < 0.01 has significant difference.
Table 6: SABC (CD3) expression compares
Note: Etretinate treatment group compares with model group, and in cerebral tissue, P < 0.0001, has statistical significant difference；P < 0.0001 in myeloid tissue, has obvious statistical significance.
3. Etretinate is to MOG(35-55)The impact of inflammatory factor in the EAE central nervous system of mice of induction
CD3 ε is the lymphocytic characterizing gene of T, the degree of inflammatory infiltration in how many reflection tissues of its content.Normal group mice is not expressed or only expresses CD3 ε on a small quantity, after giving MOG antigen immune modeling, significantly raised (the brain P=0.0004 < 0.01 of CD3 ε gene expression；Spinal cord P=0.0156, P < 0.05), there is significant difference, illustrate that inflammatory infiltration is serious.After Etretinate liquid medicine applying, CD3 ε relative expression quantity declines, and (brain P=0.003 < 0.05, in Table 7 and Fig. 3；Spinal cord P=0.0011, P < 0.01, in Table 8 and Fig. 4), there is significant difference.
Acute stage after latter 21 days of MOG immunity, proinflammatory factor IFN-γ in mouse brain white matter and myeloid tissue, IL-6, IL-17A and ROR-γ t relative expression quantity all substantially raise (P < 0.05)；Compared with model group, Etretinate treatment group IFN-γ, IL-6, IL-17A and ROR-γ tmRNA relative expression quantity substantially reduce, especially in spinal cord, IFN-γ mrna expression significantly reduces (P < 0.01, in Table 8 and Fig. 4), there is significant difference.Press down scorching factor IL-4, TGF-β, the IL-10mRNA expression compared with normal matched group in alba and spinal cord and substantially reduce (P < 0.05), and after Etretinate liquid medicine applying, expression relatively model group dramatically increases (P < 0.05, in Table 7 and Fig. 3), especially in myeloid tissue, IL-4, TGF-β 1, IL-10mRNA express and dramatically increase (P < 0.01, in Table 8 and Fig. 4), there is significant difference.
Table 7: in cerebral tissue, expression conditions compares
Note: Etretinate treatment group compares with model group, in cerebral tissue△P < 0.05, statistically significant；△△P < 0.01, has significant difference.
Table 8: in myeloid tissue, expression conditions compares
Note: Etretinate treatment group compares with model group, in myeloid tissue△P < 0.05, statistically significant；△△P < 0.01, has significant difference.
Conclusion
Experimental autoimmune encephalo myelitis model processes through Etretinate medicinal liquid intervention, can alleviate occurring degree, improves function of nervous system's effect, it is possible to alleviate inflammatory infiltration in mice pathological tissues, protects nervous tissue.
Claims (2)
1. treatment psoriasis Chinese medicine application in preparation treatment multiple sclerosis agent；The effective ingredient of wherein said treatment multiple sclerosis agent is prepared by following crude drug:
Herba Sarcandrae 15 weight portion, Rhizoma Curcumae 9 weight portion, Rhizoma Smilacis Glabrae 60 weight portion, Radix Paeoniae Rubra 9 weight portion, Fructus Mume 15 weight portion, Radix Arnebiae (Radix Lithospermi) 15 weight portion and Radix Glycyrrhizae 6 weight portion.
2. application according to claim 1, described effective ingredient is made up of following methods:
(1) by the raw material medicated powder described in claim 1, directly smash into coarse powder to pieces, add the ethanol extraction twice that 8-10 times amount volumetric concentration is 70%, each 2 hours, united extraction liquid；
(2) concentrating under reduced pressure, reclaims ethanol, prepares extractum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610188338.3A CN105749159B (en) | 2016-03-29 | 2016-03-29 | Treat application of the psoriasis Chinese medicine in preparation treatment multiple sclerosis agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610188338.3A CN105749159B (en) | 2016-03-29 | 2016-03-29 | Treat application of the psoriasis Chinese medicine in preparation treatment multiple sclerosis agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105749159A true CN105749159A (en) | 2016-07-13 |
| CN105749159B CN105749159B (en) | 2019-07-23 |
Family
ID=56345778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610188338.3A Active CN105749159B (en) | 2016-03-29 | 2016-03-29 | Treat application of the psoriasis Chinese medicine in preparation treatment multiple sclerosis agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105749159B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108498756A (en) * | 2018-04-23 | 2018-09-07 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Drug and preparation method thereof for preventing and/or treating Parkinson's disease |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101411810A (en) * | 2008-12-01 | 2009-04-22 | 车峰远 | Medicament for treating multiple sclerosis symptoms |
| CN101632827A (en) * | 2009-08-21 | 2010-01-27 | 广州中医药大学第二临床医学院 | Traditional Chinese medicine composite for treating psoriasis and preparation method thereof |
| CN101703731A (en) * | 2009-12-03 | 2010-05-12 | 蚌埠丰原涂山制药有限公司 | Chinese medicinal composition for treating multiple sclerosis |
| CN105233150A (en) * | 2015-09-29 | 2016-01-13 | 广东省中医院 | Traditional Chinese medicine composition and application thereof |
-
2016
- 2016-03-29 CN CN201610188338.3A patent/CN105749159B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101411810A (en) * | 2008-12-01 | 2009-04-22 | 车峰远 | Medicament for treating multiple sclerosis symptoms |
| CN101632827A (en) * | 2009-08-21 | 2010-01-27 | 广州中医药大学第二临床医学院 | Traditional Chinese medicine composite for treating psoriasis and preparation method thereof |
| CN101703731A (en) * | 2009-12-03 | 2010-05-12 | 蚌埠丰原涂山制药有限公司 | Chinese medicinal composition for treating multiple sclerosis |
| CN105233150A (en) * | 2015-09-29 | 2016-01-13 | 广东省中医院 | Traditional Chinese medicine composition and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 朱江等: "《现代常用针法灸法的临床应用》", 31 March 2005, 中国中医药出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108498756A (en) * | 2018-04-23 | 2018-09-07 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Drug and preparation method thereof for preventing and/or treating Parkinson's disease |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105749159B (en) | 2019-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102488879A (en) | Medicinal composition for treating rheumatism | |
| CN104274788A (en) | Traditional Chinese medicine composition for treating morbid leucorrhea due to liver-fire and damp-heat in women and preparation method of traditional Chinese medicine composition | |
| CN102988675B (en) | Traditional Chinese medicine combination for treating chronic prostatitis and preparation method thereof | |
| CN109528980A (en) | A kind of Chinese medicine composition and its pharmacy application for treating Ovary reserve decline disease | |
| Yin et al. | A proprietary herbal drug Young Yum Pill ameliorates chronic fatigue syndrome in mice | |
| CN103285206B (en) | Traditional Chinese medicinal liquor for treating rheumatic arthritis | |
| CN104383336B (en) | A kind of Chinese medicine preparation for renal calculus postoperative care and preparation method | |
| CN105194460A (en) | Traditional Chinese medicine preparation for treating acute episode stage of wind-damp-heat type gout | |
| CN103356932B (en) | A kind of pharmaceutical composition for the treatment of vulva squamous epithelial hyperplasia | |
| CN105749159A (en) | Application of traditional Chinese medicine for treating psoriasis in preparation of medicine for treating multiple sclerosis | |
| CN105250556A (en) | Traditional Chinese medicine drug for treating polycystic ovarian syndrome | |
| CN104189289B (en) | A kind of Chinese medicine for the treatment of acute icterohepatitis and preparation method thereof | |
| WO2017152834A1 (en) | Phylloporia fontanesiae and use thereof in preparing drug | |
| CN105902951A (en) | Traditional Chinese medicinal compound for treating osteosarcomas on basis of chemotherapeutic drugs | |
| CN104840865A (en) | Traditional Chinese medicine preparation for treating gouty arthritis | |
| CN110680861A (en) | A Chinese medicinal composition for treating diabetes | |
| Wu et al. | Efficacy Analysis of Wandai Decoction Combined with Traditional Chinese Medicine Fumigation and Washing in Patients with Chronic Vaginitis After Sintilimab Treatment for Small Cell Lung Cancer. | |
| CN103202938A (en) | Traditional Chinese medicine decoction for treating enteritis | |
| CN103705857B (en) | For preventing the Chinese medicine composition of oral cavity radiomucitis | |
| CN116726103A (en) | Traditional Chinese medicine composition for improving tumour cachexia and muscular atrophy as well as preparation method and application thereof | |
| CN107213426A (en) | Treat Chinese patent drug of mammary gland disease and preparation method thereof | |
| CN105343734A (en) | Traditional Chinese medicine for treating spleen and stomach qi deficiency type ulcerative colitis and preparation method | |
| CN104001025A (en) | Traditional Chinese medicine for treating chronic nephritis qi and yin deficiency and damp-heat syndrome and preparation method thereof | |
| CN105797024A (en) | Traditional Chinese medicine for treating primary liver cancer | |
| CN104758749A (en) | Traditional Chinese medicine composition for treating liver cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |